Healthspan Capital

Reservoir Neuroscience, Inc. is a biopharmaceutical company focused on developing innovative therapeutics aimed at repairing the blood-brain barrier and restoring vascular function in the brain. Founded in 2019 and located in Emeryville, California, the company targets age-related cognitive impairments and neurological disorders such as Alzheimer's disease. Its therapeutics are designed to address dysfunctional blood vessels in the brain, thereby improving disease outcomes for patients and enhancing their access to effective medical interventions.

KetoSwiss is a Swiss-based biotech startup focused on developing innovative nutraceuticals aimed at addressing metabolic dysfunctions related to neurological diseases, particularly higher-frequency migraines and conditions like Alzheimer's disease. The company creates and clinically tests medical foods designed to enhance brain energetics by providing ketone bodies as an alternative energy source when glucose utilization is impaired. Headquartered in the Technologie Park Basel, KetoSwiss operates within a vibrant ecosystem of academic research and life sciences innovation, positioning itself at the forefront of dietary preventive therapies for neurological conditions.

Repair Biotechnologies, Inc. is a biotechnology company focused on developing innovative treatments aimed at reversing immunosenescence and atherosclerosis associated with aging. Founded in 2018 and based in Syracuse, New York, the company utilizes a cholesterol-degrading platform to create therapies that target conditions driven by excess or modified cholesterol, such as atherosclerosis and familial hypercholesterolemias. Through its gene therapy and recombinant protein approaches, Repair Biotechnologies seeks to address significant age-related health issues by treating the underlying causes of these medical conditions. The company's emphasis on safety and tolerability enhances its commitment to improving patient outcomes.

Deciduous Therapeutics is a biotechnology company focused on developing innovative immune-modulatory therapies aimed at treating age-related diseases. The company specializes in novel therapeutics that activate the body's natural immune surveillance mechanisms to selectively eliminate senescent cells, which are associated with various age-related health issues. By promoting the clearance of these cells, Deciduous Therapeutics seeks to enhance healthspan and potentially improve the quality of life for individuals experiencing the effects of aging. The company is led by Anil Bhushan, a professor at UCSF, and Robin Mansukhani, who has founded multiple biotech ventures.

KetoSwiss is a Swiss-based biotech startup focused on developing innovative nutraceuticals aimed at addressing metabolic dysfunctions related to neurological diseases, particularly higher-frequency migraines and conditions like Alzheimer's disease. The company creates and clinically tests medical foods designed to enhance brain energetics by providing ketone bodies as an alternative energy source when glucose utilization is impaired. Headquartered in the Technologie Park Basel, KetoSwiss operates within a vibrant ecosystem of academic research and life sciences innovation, positioning itself at the forefront of dietary preventive therapies for neurological conditions.

Samsara Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapies for age-related diseases and unmet medical needs. Founded in 2018 and headquartered in Hamburg, Germany, with additional operations in Oxford, Paris, Graz, and San Diego, the company utilizes a unique screening platform centered on geroprotectors to create caloric restriction mimetics (CRM) that target the core mechanisms of aging, such as proteostasis, autophagy, and energy metabolism. Samsara's research and development activities include the identification, chemical optimization, and in vivo validation of compounds that aim to extend healthy lifespan and address rare genetic and neurodegenerative disorders.

Immunis is a private biotechnology company focused on creating innovative therapies to address immune decline associated with aging and various diseases. The company is developing a stem cell-derived treatment that utilizes human stem cells to generate specific populations of cells. These engineered cells are designed to secrete therapeutic factors that can help restore and modulate the immune system. By harnessing the potential of stem cells, Immunis aims to provide effective solutions for improving immune health and enhancing patient outcomes.

Metanoia Bio is a pre-clinical Biotech start-up spun out of the University of California Los Angeles (UCLA).

ImmuneBridge is focused on developing allogeneic immunotherapies for cancer by harnessing immune stem cells derived from cord blood. This innovative approach aims to create a versatile and reliable cellular source for immunotherapies, allowing for the expansion of these immune stem cells. Currently, ImmuneBridge is exploring natural killer cell-based treatments specifically for hematological cancers, with plans to extend their application to solid tumors. Their technology is designed to enhance the effectiveness of cancer treatments by utilizing a plentiful and adaptable cellular source, which holds the potential to significantly improve patient outcomes in oncology.

Shift Bioscience is focused on using advanced simulation techniques to address the challenges of aging and age-related diseases. The company has developed a high-throughput aging biomarker that facilitates the identification of rejuvenation gene factors through AI-driven cell simulations. By employing deep learning technology, Shift tests extensive gene combinations to discover potential drugs that can reverse aging effects and repair mitochondrial genes. The ultimate goal is to create a single family of drugs capable of treating various diseases associated with aging, thereby promoting sustained health into old age through accessible prescriptions.

Weatherwax Bio develops the next generation of induced-proximity medicines. The company was founded in 2019 and is based in San Francisco, California.

Reservoir Neuroscience, Inc. is a biopharmaceutical company focused on developing innovative therapeutics aimed at repairing the blood-brain barrier and restoring vascular function in the brain. Founded in 2019 and located in Emeryville, California, the company targets age-related cognitive impairments and neurological disorders such as Alzheimer's disease. Its therapeutics are designed to address dysfunctional blood vessels in the brain, thereby improving disease outcomes for patients and enhancing their access to effective medical interventions.